Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,621 to 1,640 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Coordinated transcriptional and post-transcriptional epigenetic regulation during skeletal muscle development and growth in pigs. | J Anim Sci Biotechnol | 2022 | 36457054 | PubTator, text mining | PubMed |
| Comprehensive Analysis of N6-Methyladenosine (m6A) RNA Methylation Regulators and Tumour Microenvironment Cell Infiltration Involving Prognosis and Immunotherapy in Gastroesophageal Adenocarcinomas. | Can J Gastroenterol Hepatol | 2022 | 36452120 | PubTator, text mining | PubMed |
| Analysis of m6A modulator-mediated methylation modification patterns and the tumor microenvironment in lung adenocarcinoma. | Sci Rep | 2022 | 36450735 | PubTator, text mining | PubMed |
| Biological roles of the RNA m6A modification and its implications in cancer. | Exp Mol Med | 2022 | 36446846 | PubTator, text mining | PubMed |
| RNA Modifications Meet Tumors. | Cancer Manag Res | 2022 | 36444355 | PubTator, text mining | PubMed |
| A single N6-methyladenosine site regulates lncRNA HOTAIR function in breast cancer cells. | PLoS Biol | 2022 | 36441764 | PubTator, text mining | PubMed |
| ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner. | Int J Biol Sci | 2022 | 36439881 | PubTator, text mining | PubMed |
| M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy. | Front Pharmacol | 2022 | 36438800 | PubTator, text mining | PubMed |
| N6-methyladenosine-associated prognostic pseudogenes contribute to predicting immunotherapy benefits and therapeutic agents in head and neck squamous cell carcinoma. | Theranostics | 2022 | 36438489 | PubTator, text mining | PubMed |
| The role of RNA modification in the generation of acquired drug resistance in glioma. | Front Genet | 2022 | 36437944 | PubTator, text mining | PubMed |
| Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma. | Discov Oncol | 2022 | 36434140 | PubTator, text mining | PubMed |
| Comparative Genomics and Functional Studies of Putative m6A Methyltransferase (METTL) Genes in Cotton. | Int J Mol Sci | 2022 | 36430588 | PubTator, text mining | PubMed |
| Epitranscriptome: Review of Top 25 Most-Studied RNA Modifications. | Int J Mol Sci | 2022 | 36430347 | PubTator, text mining | PubMed |
| SNP-Target Genes Interaction Perturbing the Cancer Risk in the Post-GWAS. | Cancers (Basel) | 2022 | 36428729 | PubTator, text mining | PubMed |
| N6-methyladenosine (m6A) reader Pho92 is recruited co-transcriptionally and couples translation to mRNA decay to promote meiotic fitness in yeast. | Elife | 2022 | 36422864 | PubTator, text mining | PubMed |
| Impact of WTAP in small HCC and paired adjacent non-neoplastic liver tissue on recurrence: A cohort study with external extension analysis. | Front Cell Dev Biol | 2022 | 36420139 | PubTator, text mining | PubMed |
| The genetic and biochemical determinants of mRNA degradation rates in mammals. | Genome Biol | 2022 | 36419176 | PubTator, text mining | PubMed |
| m6A modification of U6 snRNA modulates usage of two major classes of pre-mRNA 5' splice site. | Elife | 2022 | 36409063 | PubTator, text mining | PubMed |
| Expression pattern and diagnostic value of ferroptosis-related genes in acute myocardial infarction. | Front Cardiovasc Med | 2022 | 36407421 | PubTator, text mining | PubMed |
| N 6-methyladenosine RNA methylation: From regulatory mechanisms to potential clinical applications. | Front Cell Dev Biol | 2022 | 36407103 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=82